Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
Obtaining U.S. Food and Drug Administration approval for a drug, even after multiple trials in various phases, is not the easiest thing for a pharma company to do. BioMarin(NASDAQ:BMRN) knows this as well as any company that has been rejected for approval…
